10-Q: Accuray Reports Q2 Loss Amid Revenue Decline, Restructuring

Accuray Incorporated reported a significant net loss and revenue decline in Q2 2026, driven by reduced product sales and increased interest expenses, despite ongoing restructuring efforts.

Summary

• Net revenue for the three months ended December 31, 2025, decreased by 12% to $102.2 million from $116.2 million in the prior year period.
• Product revenue declined by 26% to $45.0 million, primarily due to lower shipments to China, partially offset by growth in EIMEA and Asia Pacific regions.
• Service revenue increased by 4% to $57.2 million, driven by a larger installed base and higher training and installation revenues.
• Gross profit decreased by 43% to $24.1 million, with the gross profit margin falling to 23.5% from 36.1% in the prior year.
• The company reported a net loss of $13.8 million, or $(0.11) per share, compared to a net income of $2.5 million, or $0.03 per share, in the same period last year.
• Operating expenses decreased by 4% to $35.6 million, with reductions in R&D, selling & marketing, and general & administrative expenses, but offset by $6.1 million in restructuring charges.
• Interest expense surged by 167% to $7.7 million, largely due to non-cash paid-in-kind interest and higher debt issuance costs.
• For the six months ended December 31, 2025, net revenue decreased by 10% to $196.2 million, and the net loss widened to $35.4 million from $1.4 million in the prior year.
• The company initiated a FY26 Restructuring Plan, eliminating approximately 3% of the global workforce in Q1 FY26 and 15% in Q2 FY26, with total charges expected to be around $13 million in fiscal year 2026.
• Accuray received a Nasdaq notification on February 2, 2026, regarding its common stock bid price falling below the $1.00 minimum requirement.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly negative report due to substantial declines in revenue and gross profit, a widening net loss, and significant increases in interest expense. The Nasdaq delisting warning and material weaknesses in internal controls further compound the negative outlook, despite some regional service revenue growth and delayed debt covenant enforcement.

Positives

• Service revenue increased by 4% for the three months and 5% for the six months ended December 31, 2025, indicating growth in the installed base and related services.
• Revenue growth in the EIMEA region (+11% for three months, +20% for six months) and Asia Pacific region (+42% for three months, +15% for six months) partially offset declines elsewhere.
• Operating expenses decreased by 4% for the three months and remained flat for the six months, excluding restructuring charges, reflecting cost-saving initiatives.
• Net cash used in operating activities decreased to $(3.8) million for the six months ended December 31, 2025, from $(5.5) million in the prior year, indicating improved operational cash burn.
• The company believes it has sufficient cash resources and anticipated cash flows to fund operations for at least the next 12 months.
• The commencement of the fixed charge coverage ratio and leverage ratio covenants under the Amended Financing Agreement has been delayed to December 31, 2026.

Negatives

• Overall net revenue decreased by 12% for the three months and 10% for the six months ended December 31, 2025.
• Product revenue experienced a significant decline of 26% for the three months and 25% for the six months ended December 31, 2025.
• Gross profit decreased substantially by 43% for the three months and 33% for the six months, with gross margin falling to 23.5% from 36.1%.
• The company reported a net loss of $13.8 million for the quarter and $35.4 million for the six-month period, a significant deterioration from the prior year's net income/smaller loss.
• Interest expense increased by 167% for the three months and 170% for the six months, negatively impacting profitability.
• Sales to the joint venture in China saw a substantial decrease of 57% for product sales and 5% for service sales during the three months, and 53% for product sales and 17% for service sales during the six months.
• Income from equity method investment (JV) decreased by 71% for the three months and 41% for the six months.
• The company identified two material weaknesses in its internal controls over financial reporting as of December 31, 2025, related to footnote disclosure review and analysis for complete and accurate presentation.
• Received a Nasdaq notification on February 2, 2026, regarding non-compliance with the minimum $1.00 bid price requirement, risking delisting.
• Net cash used in investing activities increased significantly to $(9.4) million from $(2.7) million for the six months.
• Net cash from financing activities shifted from providing $3.6 million to using $(0.8) million for the six months.

Risks

• The company faces risks related to the current global economic environment, including inflation, high interest rates, foreign currency exchange rate fluctuations, banking sector volatility, tightening credit markets, and geopolitical conflicts (Russia-Ukraine, Middle East, China-U.S. tensions), which could adversely affect its business, financial condition, and results of operations.
• Ongoing supply chain challenges and logistics costs, including difficulties in obtaining component materials and increased costs, are significant headwinds expected to adversely affect gross margins and net income (loss) through at least fiscal year 2026.
• Reduced budgets and lower capital deployment priority for radiotherapy equipment, along with longer customer installation timelines in the United States, have negatively impacted net revenue since fiscal year 2024 and are expected to continue through fiscal year 2026.
• The inability to maintain compliance with financial covenants (consolidated fixed charge coverage ratio, consolidated leverage ratio, minimum liquidity) in the Amended Financing Agreement could lead to default and acceleration of debt.
• Failure of CyberKnife or TomoTherapy platforms to achieve widespread market acceptance due to physician adoption, reimbursement uncertainty, or competition.
• Inability to maintain or increase gross margins on product sales and services due to manufacturing yields, production volume, selling prices, increased labor/material costs, supply chain disruptions, and tariffs.
• Intense competition and rapid technological change in the medical device industry, potentially leading to product obsolescence.
• Risks arising from international operations, including economic or political instability, changes in foreign laws and regulations, U.S. trade and economic sanctions policies, and longer payment cycles.
• Manufacturing problems, or failure of manufacturing facilities to meet federal, state, or foreign manufacturing standards, could result in delays and lost revenue.
• Exposure to product liability claims, product recalls, other field actions, and warranty claims due to defects, potentially leading to significant costs, reputational harm, and regulatory actions.
• Reliance on single-source suppliers for critical components of the CyberKnife and TomoTherapy platforms could harm the ability to meet demand in a timely and cost-effective manner.
• Dependence on key employees; failure to attract and retain qualified personnel could adversely affect business growth.
• Disruption of critical information technology systems, infrastructure, and data or cyberattacks or other security breaches or incidents could harm business and financial condition.
• Any actual or perceived failure to comply with legal or regulatory requirements related to privacy, cybersecurity, and data protection in one or multiple jurisdictions could result in proceedings, actions, or penalties.
• Implementation of artificial intelligence and machine learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences to the business.
• Continued consolidation in the healthcare industry could have an adverse effect on business, financial condition, or results of operations.
• If third-party payors do not provide sufficient coverage and reimbursement to healthcare providers for use of the CyberKnife and TomoTherapy platforms or if the number of patients covered by health insurance reduces, demand for products and revenue could be adversely affected.
• The safety and efficacy of products for certain uses is not yet supported by long-term clinical data, and products may therefore prove to be less safe and effective than initially thought.
• Failures or disruptions at third-party logistics providers have occurred and could occur in the future, which could adversely impact business.
• Third parties may claim the company is infringing their intellectual property or operating outside the scope of or violating a license or other agreement relating to their intellectual property.
• It is difficult and costly to protect intellectual property and proprietary technologies, and the company may not be able to ensure their protection.
• Identified material weaknesses in the system of internal controls as of June 30, 2025, September 30, 2025, and December 31, 2025; failure to remediate could adversely impact timely and accurate financial reporting.
• The ability to raise capital or obtain financing in the future may be limited, and failure to raise capital when needed could prevent the execution of growth strategy.
• The company may not be able to fully utilize certain tax loss carryforwards due to limitations.
• Subject to the tax laws of various foreign jurisdictions, which are subject to unanticipated changes and interpretation and could harm future results.
• The price of common stock is volatile and may continue to fluctuate significantly, which could lead to losses for stockholders.
• If the company cannot continue to satisfy the Nasdaq Global Select Market continued listing standards and other Nasdaq rules, common stock could be delisted.
• The exercise of outstanding warrants for common stock would increase the number of shares eligible for future resale in the public market and result in dilution to stockholders.
• The conditional conversion features of the 2026 Notes, if triggered, may adversely affect financial condition and operating results.
• Provisions in the indenture for the 2026 Notes, the financing agreement for Credit Facilities, certificate of incorporation, and bylaws could discourage or prevent a takeover.
• Liquidity could be adversely impacted by adverse conditions in the financial markets.
• Operations are vulnerable to interruption or loss because of climate change, natural disasters, global or regional health pandemics or epidemics, terrorist acts, and other events beyond control.

Future Outlook

Accuray expects inflation, ongoing supply chain challenges, and heightened logistics costs to continue impacting cash from operations and adversely affecting gross margins and net income (loss) through at least fiscal year 2026, and potentially longer. Reduced budgets and lower capital deployment priority for radiotherapy equipment, along with longer customer installation timelines in the United States, are anticipated to negatively impact net revenue through fiscal year 2026. The company also faces significant tariff uncertainty related to U.S.-China trade, which is expected to continue impacting sales to China and financial results.

Management Comments

• We expect that the business of our customers and our own business will continue to be adversely impacted, directly or indirectly, by these macroeconomic and geopolitical issues.
• We currently expects that gross margins and net income (loss) will continue to be adversely affected by increased material costs and freight and logistics expenses through at least fiscal year 2026, and potentially longer.
• We expect inflation and the ongoing supply chain challenges and logistics costs to impact our cash from operations through at least fiscal year 2026.
• Reduced budgets and lower capital deployment priority for radiotherapy equipment, along with longer customer installation timelines, in the United States have negatively impacted our net revenue since fiscal year 2024, and we expect this will continue to have an impact through fiscal year 2026.
• We believe that our current cash and cash equivalents balance will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for at least the next 12 months.
• We continue to critically review our liquidity and anticipated capital requirements in light of the significant uncertainty created by macroeconomic conditions.
• We cannot predict the full impact or timing of such efforts and expect that sales to China will be adversely impacted, and our financial results have been adversely impacted in the past and may continue to be adversely impacted in the future.

Industry Context

StockSavvy.ai notes that the medical device industry, particularly in non-invasive cancer treatment, faces intense competition and rapid technological change. Accuray's challenges with declining product revenue, especially in China, reflect broader geopolitical and macroeconomic headwinds affecting global trade and supply chains. The increased interest rates and inflation are impacting capital expenditure decisions for healthcare providers, a trend observed across the industry. The company's reliance on its joint venture in China, a market with significant growth potential but also regulatory and political uncertainties, highlights the complexities of international expansion in this sector. Competitors like Varian Medical Systems (part of Siemens Healthineers) and Elekta AB, with larger market shares and resources, continue to pose significant competitive threats, especially as they also develop advanced radiotherapy systems.

Comparison to Industry Standards

• Accuray's gross profit margin of 23.5% for the three months ended December 31, 2025, is significantly lower than typical medical device industry benchmarks, which often range from 50% to 70% for established product lines, indicating substantial pressure from increased material costs and product mix.
• The 51% decline in product sales to China for the three months ended December 31, 2025, contrasts sharply with the general growth trajectory expected in the Chinese radiation oncology market, which is considered the world's largest growth market for such systems, suggesting Accuray is underperforming relative to market potential or facing specific competitive/geopolitical challenges.
• The increase in interest expense by 167% for the three months ended December 31, 2025, reflects a higher cost of capital compared to many industry peers who may have more favorable debt structures or stronger balance sheets, making Accuray's debt servicing more burdensome.
• The Nasdaq minimum bid price non-compliance is a significant concern, as major competitors like Varian (part of Siemens Healthineers) and Elekta maintain strong stock market positions and liquidity, indicating Accuray's stock performance is lagging behind industry standards and potentially impacting investor confidence.

Management Changes

Corporate Governance

Legal Proceedings

• No probable and reasonably estimable material losses related to any current legal proceedings and claims.
• The company is subject to potential product liability claims, product recalls, other field actions, and warranty claims inherent in the medical device business.
• The company is subject to claims of intellectual property infringement by third parties.
• The company is subject to federal, state, and foreign laws and regulations applicable to its operations, including healthcare laws, anti-corruption laws, privacy rules, and transparency laws, with potential for substantial penalties for violations.
• The company is subject to potential legal proceedings related to AI and machine learning technologies, including errors, bias, or improper processing of personal information.
• The company is subject to potential civil lawsuits and class actions relating to breaches of consumer data.

Related Party Transactions

• On October 18, 2025, the company entered into a consulting agreement with Dedication Capital, LLC, an affiliate of Steven F. Mayer (a board member).
• Mr. Mayer was appointed as Transformation Board Sponsor, providing consulting services for one year.
• Compensation includes a base consulting fee of $600,000 per year, a cash incentive award up to $750,000 for FY26 and the first 3 months of FY27, and equity awards consisting of 1.25 million restricted stock awards (RSAs) and 1.25 million performance-based stock awards (PRSAs).
• The company recorded $0.2 million for consulting fees and incentive target bonus, and $0.2 million in stock compensation expense for the RSAs and PRSAs, during both the three and six months ended December 31, 2025.
• Consulting fees and incentive target bonus are included in restructuring expenses.

Stakeholder Impact

• Shareholders: Negative impact due to significant net losses, declining revenue, gross margin compression, increased interest expense, and the Nasdaq delisting warning. Potential dilution from warrant exercises and future capital raises.
• Employees: Impacted by the FY26 Restructuring Plan, which includes the elimination of approximately 18% of the global workforce.
• Customers: Potential delays in product shipments and installations due to macroeconomic factors and supply chain challenges. Reduced budgets and lower capital deployment priority for radiotherapy equipment in the US may affect purchasing decisions.
• Lenders: The company's ability to comply with debt covenants is a concern, though some covenant commencements have been delayed. Assets are pledged as collateral.
• Suppliers: Ongoing supply chain challenges and increased material costs may affect relationships and pricing.

Next Steps

• Regain compliance with Nasdaq's minimum $1.00 bid price requirement within 180 calendar days.
• Continue implementing remediation efforts for identified material weaknesses in internal controls over financial reporting.
• Complete the FY26 Restructuring Plan, expected to be substantially finished by June 30, 2026.
• File a registration statement for the resale of warrant shares, with an extended due date.
• Address the maturity of the $18.0 million Convertible Senior Notes due June 1, 2026, using operating cash and/or Delayed Draw Facility proceeds.
• Monitor and manage compliance with financial covenants (Total Leverage Ratio, Fixed Charge Coverage Ratio, Liquidity) under the Amended Financing Agreement, with commencement delayed to December 31, 2026.
• Continue efforts to mitigate impacts of inflation, supply chain challenges, and logistics costs through at least fiscal year 2026.
• Address the negative impact on net revenue from reduced budgets and longer customer installation timelines in the United States through fiscal year 2026.
• Navigate tariff uncertainties and their impact on sales to China.

Key Dates

Recommendation

Accuray's Q2 2026 results show a severe deterioration in financial performance, with substantial revenue decline, gross profit compression, and a widening net loss. The significant increase in interest expense further burdens profitability. The Nasdaq delisting warning indicates severe market underperformance and raises concerns about the company's long-term viability and access to capital. While restructuring efforts are underway, the immediate financial outlook is highly negative, and material weaknesses in internal controls add to the risk profile. The substantial decline in sales to the critical China joint venture is particularly troubling. These factors collectively point to significant downside risk for investors.

Keywords

Accuray, ARAY, Medical Devices, Radiation Therapy, Oncology, CyberKnife, TomoTherapy, Radixact, SEC Filing, 10-Q, Financial Results, Net Loss, Revenue Decline, Restructuring, Debt Financing, Warrants, Nasdaq Listing, Internal Controls, China Joint Venture, Supply Chain, Inflation, Geopolitical Risks, Healthcare Industry, Capital Expenditures, Shareholder Dilution